JAM
IMVT icon

Jupiter Asset Management’s Immunovant IMVT Stock Holding History

Jupiter Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,165
Closed -$470K – 472
2023
Q4 		$470K Buy
+11,165
New +$411K ﹤0.01% 417
2023
Q1 		– Sell
-42,082
Closed -$745K – 457
2022
Q4 		$745K Buy
+42,082
New +$530K 0.01% 389

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Jupiter Asset Management's IMVT Position: Q1 2024 in Review

Jupiter Asset Management sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 11,165 shares — an estimated $470K sold.

Jupiter Asset Management first reported a position in IMVT in Q4 2022 and held it in 2 quarters. The position peaked at $745K in Q4 2022. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

  • Jupiter Asset Management reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
  • Jupiter Asset Management sold 11,165 Immunovant shares in Q1 2024, an estimated $470K.
  • Jupiter Asset Management first reported a position in Immunovant in Q4 2022 and held it in 2 quarters.
  • Jupiter Asset Management's Immunovant position peaked at $745K in Q4 2022.
  • 209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Jupiter Asset Management's 13F filing for Q1 2024, filed 10 May 2024.